Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial
Open-label, no control groupHumansWith Equisetum arvense (horsetail)
This study tested palmitoylethanolamide together with Equisetum arvense (horsetail). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 50 patients with chronic pain (low back pain and radiculopathy for two months) enrolled at one centre. 49 completed.
- Dose used in the study
- Tablets with 600 mg of palmitoylethanolamide and 300 mg of Equisetum arvense: two a day for 2 weeks, then one a day for 6 weeks
- Duration
- 8 weeks
- What was measured
- Pain intensity on two rating scales, pain descriptors, patient satisfaction and quality of life.
What the authors reported
This trial found:
- Pain fell 3.8 points on the numeric pain rating scale and 2.1 points on the verbal rating scale (p < 0.0001), and quality of life rose 35%.
- The authors classed 46 of 49 patients as responders.
- No adverse events were reported.
Limits of this study
A before-and-after study with no placebo or comparison group, at one centre. The authors name these limits. The funding statement was not visible on the page checked.
Source
PubMed 40981167 · doi:10.3390/medsci13030169
Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.